Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.
From Treatable Traits to Personalized Medicine in COPD: T2 Inflammation and Its Impact on Patient Assessment and Treatment
6
episodes
0.50 program credits
36m
Choose a format
Take Program Post-Test
Program Post-Test Completed
Details
Presenters
Overview
Disclosure of Conflict of Interest
Faculty Disclosures
Surya Bhatt, MD, MSPH
Advisory Boards: Chiesi, Genentech, GlaxoSmithKline
Consultant: Apreo, Boehringer Ingelheim, Regeneron, SanofiMeiLan Han, MD, MS
Advisory Boards: Medtronic, Novartis
Consultant: Aerogen, Altesa Bio, AstraZeneca, Boehringer Ingelheim, DevPro, GlaxoSmithKline, Merck, Mylan, Novartis, Polarian, Pulmonx, Regeneron, Sanofi, Teva, VeronaAccreditor Disclosures
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.Target Audience
This activity is designed for US-based pulmonologists, internal medicine clinicians, and nurse practitioners and physician assistants.
Learning Objectives
Upon completion, participants should be able to:
- Describe the role of T2 inflammation in COPD disease burden
- Assess patients with new and established COPD for the presence of T2 inflammation
- Discuss therapies in development that target T2 inflammation in COPD, including their treatment targets and available evidence to data supporting use
- Apply personalized medicine strategies to the management of patients with COPD
Accreditation and Credit Designation Statements
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity CE, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provider(s)/Educational Partner(s)
This activity is provided by Integrity CE, LLC.
Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Publication Dates
Release Date:
Expiration Date:
